Lv1
35 积分 2021-01-21 加入
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
12天前
已完结
BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
13天前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
13天前
已完结
Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study
13天前
已关闭
Nodular lymphocyte-predominant Hodgkin lymphoma controversy and insights: a global NLPHL one working group summit report
16天前
已完结
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
16天前
已完结
Antibody–drug conjugates in gynaecological cancers: opportunities and challenges
18天前
已完结
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
25天前
已完结
实体肿瘤PD-L1免疫组织化学检测专家共识（2021版）
26天前
已完结
Biology and regulation of IL-2: from molecular mechanisms to human therapy
26天前
已完结
皖公网安备34019202002308
